Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions: Fludarabine, Melphalan, Total Body Irradiation; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 25
States / cities: Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Influenza
Interventions: CAIV-T, TIV, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Healthy Adults
Interventions: Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3, Vaccine Candidate #4, Vaccine Candidate #5, Vaccine Candidate #6, TIV1 or TIV2; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 770 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Mobile, Alabama • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Pregnancy Related, Influenza, Human
Interventions: There is no intervention.; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Fluarix, GSK Biologicals Influenza Vaccine GSK576389A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more

Conditions: Influenza
Interventions: Monovalent influenza A/H7N9 virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1073, mRNA-1010, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 14
States / cities: Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more

Conditions: Infection, Leukemia
Interventions: trivalent influenza vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 1 Year to 20 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Hackensack, New Jersey • Buffalo, New York

Conditions: Influenza Immunization
Interventions: Pandemic flu H5 mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more

Conditions: Influenza
Interventions: Auto-injector for IM/SC vaccine administration; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Viral Lung Infection and Acute Respiratory Failure
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 72
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more

Conditions: Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer
Interventions: Flucelvax, Fluvirin, Fluzone High Dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza, Orthomyxoviridae Infections
Interventions: Monovalent subvirion H5N1 influenza vaccine, Physiological saline; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more

Conditions: Healthy
Interventions: Sucrose, Galactooligosaccharide; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions: School-located Influenza Vaccination Clinic; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Years to 19 Years
Enrollment: 20,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: NasoVAX; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017, naproxen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Search by objective public record fields.

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NK Cell Mediated Influenza Immunity During Pregnancy

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

H5 Adult - Chiron Study of Bird Flu Vaccine

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

H7N9 Boost in Healthy Adults

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

Galactooligosaccharide, Immune Strength, and Digestive Health

Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)